Rachel McMinn - 26 Mar 2025 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role
Chief Executive Officer, Director
Signature
/s/ Christine Mikail, as attorney-in-fact for Rachel McMinn
Issuer symbol
NGNE
Transactions as of
26 Mar 2025
Net transactions value
$0
Form type
4
Filing time
28 Mar 2025, 21:27:40 UTC
Previous filing
25 Nov 2024
Next filing
24 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NGNE Common Stock Award $0 +23,900 +1.9% $0.000000 1,274,259 26 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGNE Employee Stock Option (Right to buy) Award $0 +143,500 $0.000000 143,500 26 Mar 2025 Common Stock 143,500 $16.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consist of 23,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
F2 This option represents the right to purchase 143,500 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.